UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer

被引：0

作者：

R Petrioli

M Sabatino

A I Fiaschi

S Marsili

D Pozzessere

S Messinese

P Correale

S Civitelli

G Tanzini

F Tani

A De Martino

G Marzocca

M Lorenzi

G Giorgi

G Francini

机构：

[1] Medical Oncology Section,Department of Human Pathology and Oncology

[2] University of Siena,Department of Pharmacology

[3] Viale Bracci 11,undefined

[4] University of Siena,undefined

[5] Clinical Surgery,undefined

[6] University of Siena,undefined

[7] General Surgery,undefined

[8] University of Siena,undefined

来源：

British Journal of Cancer | 2004年 / 90卷

关键词：

colorectal cancer; irinotecan; oxaliplatin; tegafur/uracil;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

A total of 41 metastatic colorectal cancer (CRC) patients received tegafur/uracil (UFT)+leucovorin (LV)+oxaliplatin alternated with UFT/LV+irinotecan. The overall response rate was 58.5% (95% confidence interval, 42.2–73.3%), and the median progression-free survival was 8.8 months. There were no grade 4 toxicities; 12 patients (29%) experienced grade 3 diarrhoea. There were no cases of hand–foot syndrome. This alternating regimen seems to be effective and well tolerated in the first-line treatment of patients with metastatic CRC.

引用

页码：306 / 309

页数：3

共 50 条

[11] UFT and leucovorin in metastatic colorectal cancer: clinical insights
Van Cutsem, E
ANTI-CANCER DRUGS, 2003, 14 : S1 - S1
[12] Dual modulation of UFT with leucovorin and hydroxyurea in metastatic colorectal cancer
Jakobsen, A
Pfeiffer, P
Hansen, F
Sandberg, E
Aabo, K
ACTA ONCOLOGICA, 2001, 40 (01) : 63 - 66
[13] UFT plus leucovorin for metastatic colorectal cancer: Japanese experience
Ichikawa, W
Nihei, Z
Uetake, H
Yamada, H
Shirota, Y
Sugihara, K
ONCOLOGY-NEW YORK, 2000, 14 (10): : 41 - 43
[14] Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer
Siemerink, Ester J. M.
Drenth, Annemieke F. J.
Mulder, Nanno H.
Plukker, John T. M.
Hospers, Geke A. P.
GASTRIC CANCER, 2010, 13 (02) : 95 - 100
[15] Phase II study of oxaliplatin, UFT, and leucovorin in patients with metastatic gastric cancer
Ester J. M. Siemerink
Annemieke F. J. Drenth
Nanno H. Mulder
John T. M. Plukker
Geke A. P. Hospers
Gastric Cancer, 2010, 13 : 95 - 100
[16] Irinotecan and UFT/leucovorin in patients with advanced cancers
Stevenson, JP
Redlinger, M
Sun, WJ
Haller, D
O'Dwyer, PJ
ONCOLOGY-NEW YORK, 2000, 14 (10): : 91 - 92
[17] Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI): first-line therapy for metastatic colorectal cancer
J-P Delord
J Bennouna
P Artru
H Perrier
F Husseini
F Desseigne
E François
R Faroux
D Smith
P Piedbois
H Naman
J Y Douillard
R Bugat
British Journal of Cancer, 2007, 97 : 297 - 301
[18] Phase II study of UFT with leucovorin and irinotecan (TEGAFIRI):: first-line therapy for metastatic colorectal cancer
Delord, J-P
Bennouna, J.
Artru, P.
Perrier, H.
Husseini, F.
Desseigne, F.
Francois, E.
Faroux, R.
Smith, D.
Piedbois, P.
Naman, H.
Douillard, J. Y.
Bugat, R.
BRITISH JOURNAL OF CANCER, 2007, 97 (03) : 297 - 301
[19] Irinotecan/Fluorouracil/Leucovorin or the Same Regimen Followed by Oxaliplatin/Fluorouracil/Leucovorin in Metastatic Colorectal Cancer
Kalofonos, Haralabos P.
Papakostas, Pavlos
Makatsoris, Thomas
Papamichael, Demetrios
Vourli, Georgia
Xanthakis, Ioannis
Aravantinos, Gerasimos
Papadimitriou, Christos
Pentheroudakis, George
Varthalitis, Ioannis
Samelis, George
Syrigos, Kostas N.
Xiros, Nikolaos
Stavropoulos, Michalis
Kosmidis, Paris
Christodoulou, Christos
Linardou, Helen
Skondra, Maria
Pectasides, Dimitrios
Economopoulos, Theofanis
Fountzilas, George
ANTICANCER RESEARCH, 2010, 30 (10) : 4325 - 4333
[20] Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer
Veronese, ML
Stevenson, JP
Sun, W
Redlinger, M
Algazy, K
Giantonio, B
Hahn, S
Vaughn, D
Thorn, C
Whitehead, AS
Haller, DG
O'Dwyer, PJ
EUROPEAN JOURNAL OF CANCER, 2004, 40 (04) : 508 - 514

← 1 2 3 4 5 →